Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* - Informed consent obtained~* - Type 1 diabetes mellitus for 12 months or longer~* - Basal bolus or CSII (Continuous Subcutaneous Insulin Infusion, insulin pump) treatment for 6 months or longer~* - Stable insulin treatment for the last 3 months prior to Screening, as judged and documented by the investigator~* - HbA1c 7.0-10% (Diabetes Control and Complications Trial (DCCT)), both inclusive, (corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))~* - Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, complete trial related questionnaires, diaries, self-monitoring of plasma glucose, self titration of insulin and attend all scheduled visits~Exclusion Criteria:~* - Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPP-4) inhibitors~* - Use of any medication, which in the investigator's opinion could interfere with the glycaemic control or affect the subject's safety.Premix insulin is not allowed~* - Known proliferative retinopathy or maculopathy requiring acute treatment~* - Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator~* - Uncontrolled/ untreated blood pressure at screening above 160 mmHg for systolic or above 100 mmHg for diastolic~* - History of acute or chronic pancreatitis~* - Screening calcitonin value equal to or above 50 ng/L~* - Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2)~* - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide 0.6 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 1.2 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 1.8 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide placebo 0.6 mg + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 1.2 mg + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 1.8 mg + insulin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).